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Abstract: Although notable progress has been made in the treatment of non-small-cell lung cancer (NSCLC) in recent 
years, this disease is still associated with a poor prognosis. Despite early-stage NSCLC is considered a potentially curable 
disease following complete resection, the majority of patients relapse and eventually die after surgery. Adjuvant chemo-
therapy prolongs survival, altough the absolute improvement in 5-year overall survival is only approximately 5%. 
Trying to understand the role of genes which could affect drug activity and response to treatment is a major challenge for 
establishing an individualised chemotherapy according to the specific genetic profile of each patient. Among genes in-
volved in the DNA repair system, the excision repair cross-complementing 1 (ERCC1) is a useful markers of clinical re-
sistance to platinum-based chemotherapy. In the International Lung Cancer Trial (IALT) adjuvant chemotherapy signifi-
cantly prolonged survival among patients with ERCC1 negative tumors but not among ERCC1-positive patients. BRCA1 
and ribonucleotide reductase M1 (RRM1), two other key enzymes in DNA synthesis and repair, appear to be modulators 
of drug sensitivity and may provide additional information for customizing adjuvant chemotherapy.  
Several clinical trials suggest that overexpression of class III -tubulin is an adverse prognostic factor in cancer since it 
could be responsible for resistance to anti-tubulin agents. A retrospective analysis of NCIC JBR.10 trial showed that high 
tubulin III expression is associated with a higher risk of relapse following surgery alone but also with a higher probability 
of benefit from adjuvant cisplatin plus vinorelbine chemotherapy. 
Finally, the use of gene expression patterns such as the lung metagene model could provide a potential mechanism to re-
fine the estimation of a patient’s risk of disease recurrence and could affect treatment decision in the management of early 
stage of NSCLC.  
In this review we will discuss the potential role of pharmacogenomic approaches to guide the medical treatment of early 
stage NSCLC. 
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INTRODUCTION 
  Worldwide lung cancer accounts for the largest number 
of new cases of cancer and results in about 1 million of deaths/ 
year [1]. For early-stage non small cell lung cancer (NSCLC) 
surgical lung resection is the treatment of choice; however, 
five-years survival rates range from 30% to 60% [2]. 
  The role of adjuvant chemotherapy for resected early 
stage NSCLC was still an open question until few years ago, 
but currently it represents the standard treatment for patients 
with resected stage II-III disease. The results of the meta-
analysis by the British Medical Research Council have dem-
onstrated that cisplatin-based adjuvant chemotherapy for 
stage I through III NSCLC causes a non statistically signifi-
cant advantage in survival of 5% at five years [3]. The first 
phase III clinical trials conducted after the meta-analysis 
have failed to demonstrate a significant benefit with adjuvant 
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chemotherapy [4-6]. However, adjuvant chemotherapy has 
recently been re-evaluated in several clinical trials [7-12]. 
The International Adjuvant Lung Trial (IALT) reported a 
statistically
  significant 4% survival advantage at 5 years 
[hazard ratio (HR):
 0.86; P< 0.03] with the addition of four 
cycles of cisplatin-based
 chemotherapy after complete resec-
tion of stage I–III NSCLC. The study was not stratified
 to 
evaluate results by stage, but a trend toward a greater benefit
 
in stage II and III patients was identified [7]. In the JBR.10 
trial patients with completely resected stage IB–IIB
 NSCLC 
were randomized to receive four cycles of chemotherapy 
(cisplatin/ vinorelbine) or only
 observation [9]. A 15% sur-
vival advantage was reported at 5
 years (HR:0.70; P=0.012) 
in the chemotherapy arm.
 The trial was stratified by stage, 
and, in a subset analysis,
 no benefit was noted for stage IB 
patients (HR:0.94). In the only adjuvant trial to use a car-
boplatin-based regimen (CALGB 9633) in patients with re-
sected stage IB NSCLC receiving adjuvant chemotherapy a 
survival advantage was initially reported. This trial was 
closed early when the first interim analysis
 demonstrated a 
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an update of the CALGB 9633 study, which was presented at 
the American Society of
  Clinical Oncology (ASCO) 2006 
Annual Meeting showed no significant survival advantage 
for adjuvant chemotherapy [11]. Confirmation of beneficial 
role of adjuvant therapy
 was also demonstrated in the Adju-
vant Navelbine
  International Trialist Association (ANITA) 
trial. In this study, patients with resected NSCLC had a 9% 
survival advantage at
 5 years (HR:0.79; P=0.013) with adju-
vant chemotherapy (cisplatin/vinorelbine), but no benefit 
was found for
 stage IB NSCLC patients [HR:1.10; 95% con-
fidence
 interval (CI), 0.76–1.57] [12]. 
  An individual patient meta-analysis (LACE) of the five 
largest cisplatin-based
 studies (ALPI, BLT, IALT, JBR.10, 
and ANITA) has been conducted. This study found
 a 5.3% 
absolute survival advantage at 5 years (HR:0.89; 95%
  CI, 
0.82–0.96; P=0.004) for adjuvant cisplatin therapy.
 However, 
this benefit depends on stage and is greatest in patients with 
stages II and III (HR:0.83; 95% CI, 0.73–0.95) while a det-
riment for chemotherapy was suggested in stage IA patients
 
(HR:1.41; 95% CI, 0.96–2.09) [13].  
  Therefore, adjuvant cisplatin-based chemotherapy is cur-
rently recommended for fully resected stage II and III 
NSCLC [14].  
  Moreover, the majority of patients, which are enrolled in 
clinical trials of adjuvant chemotherapy are patients selected 
for relative better prognostic factors, such as younger age, 
good performance status (PS) and clinically fit to receive 
platinum-based chemotherapy. Therefore, these results are 
not directly translatable to daily clinical practice. Further, 
there are no data regarding the role of adjuvant chemother-
apy in patients with pure bronchioloalveolar histology carci-
noma, in elderly patients (age> 75 years) and in patients re-
ceiving adjuvant treatment after two months from surgery. 
Sex, histologic type, age and other clinical variables are vali-
dated prognostic factor but do not allow to select those pa-
tients who could benefit from chemotherapy [7,13]. Stage is 
still the most important factor to consider when administer-
ing adjuvant treatment. However, there is a need for new 
approaches including the use of molecular markers for se-
lecting patients who are most likely to benefit from a given 
adjuvant therapy.  
MOLECULAR PROGNOSTIC AND PREDICTIVE 
FACTORS  
  Recently, an increasing body of experimental evidence 
has been provided to link tumor-specific molecular charac-
teristics, such as epidermal growth factor receptor (EGFR) 
mutations and/or EGFR gene copy number with response
 to 
the EGFR inhibitors gefitinib
  and erlotinib in metastatic 
NSCLC [15-17]. Likewise, current data suggest that several 
molecular markers may be predictive of response to specific 
cytotoxic drugs in certain subpopulation of NSCLC patients. 
Excision Repair Cross-Complementation Group 1 
(ERCC-1) and Ribonucleotide Reductase Subunit M1 
(RRM1) 
ERCC1 
  Platinum compounds exert their cytotoxic effects by 
binding covalently to genomic DNA, forming adducts that 
result in altered forms of DNA thus interfering with normal 
cellular replication. To maintain the structural integrity of 
DNA, an intricate network of DNA repair systems is in-
volved. One of the most important is the nucleotide excision 
repair (NER), a highly versatile and sophisticated DNA 
damage removal pathway. ERCC-1 is component of the 
NER complex, and could be measured to assess the func-
tional status of this pathway. It forms a molecular complex 
with another protein, belonging to the xeroderma pigmento-
sum group F (XPF), and removes modified nucleotides to-
gether with adjacent nucleotides from the damaged strand 
during the first step (excision), which is followed by synthe-
sis of an intact strand through DNA polymerase activity (re-
pair synthesis) [18]. In vitro studies
  have linked platinum 
resistance to the expression of ERCC1 messenger
  RNA 
(mRNA) in ovarian, cervical, testicular,
 bladder and NSCLC 
cancer cell lines [19]. The relationship
 between the expres-
sion of ERCC1 mRNA and platinum resistance has been 
observed in small, retrospective clinical
 trials in patients with 
several malignancies such advanced gastric, ovarian, colo-
rectal,
  esophageal, or NSCLC [20-23].
.Furthermore,
  two 
common polymorphisms of the ERCC1 gene [24-27] (codon
 
118 C/T and C8092A) have been correlated with the re-
sponse to
 platinum-based chemotherapy in colorectal cancer
 
[28] and NSCLC [29]. These polymorphisms are mainly 
associated with
 lower rates of translation of the ERCC1 gene, 
which results
 in low levels of the protein into the nuclei. 
  The influence of ERCC-1 on resistance to chemotherapy 
in the adjuvant setting of NSCLC patients has been evalu-
ated in a retrospective analysis of the IALT trial. Seven hun-
dred and sixty one tumor specimens were analyzed to evalu-
ate the expression of ERCC-1 protein by immunohistochem-
istry (IHC). Among these, 426 (56%) samples were scored 
as negative, while 335 (44%) samples were ERCC1-positive. 
A Multivariate logistic model showed that the expression of
 
ERCC1 was significantly correlated with age (P=0.03; less 
common
  in patients younger than 55 years of age than in 
patients 55
 to 64 years of age), histologic type (P<0.001; less 
common
  in adenocarcinomas than in squamous-cell carci-
nomas), and pleural
  invasion (P=0.01; less common in the 
absence than in the presence
 of pleural invasion). 
 
  Among patients with ERCC1-negative tumors, overall 
survival (OS) was significantly longer in the chemotherapy 
group compared to surgery alone (HR:0.65; 95% CI,
 0.50 to 
0.86; P=0.002). Median survival time (MST) resulted 14
 
months longer in patients receiving adjuvant treatment (56 
months)
 than in the control group (42 months). Also disease 
free survival (DFS) in ERCC1-negative patients was longer 
in the chemotherapy group than in the control group (HR: 
0.65; 95% CI, 0.50 to
 0.85; P=0.001). ERCC1-positive pa-
tients did not experience any benefit from adjuvant cisplatin 
based chemotherapy compared with ERCC1-positive pa-
tients in the control group (HR:1.14;
 95% CI, 0.84 to 1.55; 
P=0.40). Analyzing exclusively patients in the control
 group, 
the 5-year overall survival (OS) rate was significantly higher 
(46%)
 among patients with ERCC1-positive tumors as com-
pared to ERCC1-negative patients (39%) (HR:0.66 95%
 CI, 
0.49 to 0.90; P=0.009) [30]. These results led to the hypothe-
sis that determination of ERCC1 expression in
 fully resected 
NSCLC can
 be an independent predictor of the efficacy
 of 
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  With the increasing evidence supporting ERCC-1 expres-
sion as a marker of platinum resistance and worse prognosis 
in patients with metastatic NSCLC [31-32], several research 
groups are planning prospective clinical trials using ERCC1 
to guide treatment decisions. 
  The first prospective trial testing the concept of custom-
ized chemotherapy in NSCLC is a phase III study in which 
four hundred and forty four metastatic NSCLC patients were 
randomly assigned in a 1:2 ratio to either the control arm or 
the genotypic arm. According to ERCC1 mRNA baseline 
levels,
 patients received cisplatin plus docetaxel (low ERCC1 
mRNA),
 or a non platinum-based regimen, such as gemcit-
abine plus
  docetaxel (high ERCC1 mRNA), while all pa-
tients in the control arm received cisplatin
  plus docetaxel.
 
Among 346 patients assessable for response (primary end-
point), 53 patients (39.3%) in the control arm and 107 pa-
tients (51.2%) in the genotypic arm achieved
 objective re-
sponse (one-sided Fisher's exact test, P=0.02). In an explora-
tory analysis of response, the genotypic arm was subdivided 
into
 the low and high ERCC-1 mRNA level groups. Sixty-
five patients (53.2%) in the low genotypic group, and 42 
patients
 (47.2%); in the high genotypic group
 achieved objec-
tive responses [33]. There was no difference in survival rates 
between the two treatment strategies (9.8 months in the con-
trol arm vs 9.9 months in genotypic arm P=0.59), although 
the study was not powered to assess survival as its primary 
end point [33].  
RRM1 
  Another key enzyme in DNA synthesis and repair is the 
ribonucleotide reductase. It is the only known enzyme that 
converts ribonucleotides into deoxyribonucleotides which 
are required for DNA synthesis and repair. The ribonucleo-
tide reductase consists of two dimerized subunits (RRM1 
and RRM2), whose dimerization is required for DNA syn-
thesis [34]. 
  RRM1 gene expression has been identified as a potential 
pharmacogenetic marker of gemcitabine resistance. Gemcit-
abine (2’, 2’-difluorodeoxycitidine) is one of the most 
widely used cytotoxic drugs for NSCLC treatment, which 
interfere with ribonucleotide reductase [35,36]. The overex-
pression of RRM1 has been linked to the tumor resistance to 
platinum drugs and gemcitabine [32] while high expression 
of RRM1 is a positive prognostic marker for survival proba-
bly because its induces phosphatase and tensin homolog 
(PTEN) expression and inhibit cell migration, invasion, and 
metastasis formation [37,38]. 
  Retrospective data from patients with stage IV NSCLC 
have provided evidence that RRM1 mRNA expression is a 
key predictive marker of survival in patients treated with 
gemcitabine plus cisplatin [39,40]. 
  The correlation between ERCC1, RRM1 mRNA levels 
and shortened survival has been observed by Ceppi et al. in 
advanced NSCLC patients receiving platinum- and gemcit-
abine-based chemotherapy [32]. Recently, Zheng et al. have 
analyzed RRM1, ERCC1 and PTEN protein expression with 
an automated quantitative determination, in histological 
specimens from early stage (stage I) NSCLC patients treated 
with surgery alone. RRM1 expression correlated with the 
expression of ERCC1 (P< 0.001), but not with the expres-
sion of PTEN (P=0.37). The DFS in patients with RRM1 
high levels was more than 120 months compared to the DFS 
of 54.5 months observed in patients with low RRM1 levels; 
this difference was statistically significant (P=0.004 HR for 
low vs high expression, 2.2). The median OS was 120 
months and 60 months, respectively (HR:0.60; P=0.02). In 
this trial the expression of RRM1 was not associated with 
tumour stage, histologic type, age, sex, Eastern Cooperative 
Oncology Group (ECOG) PS, absence or presence of weight 
loss and smoking status. The investigators confirmed that 
RRM1 expression correlate with the expression of ERCC1 
(P=0.001). One hundred and eighty four patients whose tu-
mor specimens were scored for both proteins were separated 
in four group. Only patients who had high expression of both 
proteins had a median DFS and median OS of more than 120 
months, that were significantly longer than those for patients 
in the other groups (P=0.01 for DFS, P=0.02 for the OS). 
These data suggest that the concomitant high expression of 
both proteins delineate a subgroup of patients (approxi-
mately 30%) with a relatively better outcome [41].  
  A prospective, phase
 II clinical trial that used tumor ex-
pression of RRM1 and ERCC1 mRNA as detected by real-
time quantitative polymerase chain
 reaction (RT-QPCR) for 
selection of chemotherapy in advanced NSCLC patients has 
been recently conducted. This strategy resulted
 in four possi-
ble gene expression strata with the following therapies: the 
low RRM1 and low ERCC1 group (gemcitabine and
  car-
boplatin treatment group); low RRM1 and high
  ERCC1 
group (gemcitabine and docetaxel treatment group); the high 
RRM1 and
  low ERCC1 group (docetaxel and carboplatin 
treatment group); the high RRM1 and high ERCC1 group 
(docetaxel
 and vinorelbine treatment group). Among eighty 
five patients enrolled, sixty underwent tumor biopsy and 
gene expression analysis was performed in fifty five patients. 
Response Rate (RR) was 44%, OS was 59% and PFS 14%
 at 
1 years, with a median of 13.3 and 6.6 months, respectively 
[42]. Considering these data,
 a prospective phase II clinical 
trial to assess the efficacy of selecting chemotherapy regi-
mens (with or without platinum, and with or without gemcit-
abine) based on ERCC1 and RRM1 tumor expression in ad-
juvant setting of NSCLC has been planned by the Southwest 
Oncology Group (SWOG).  
p27 
kip1 
  Biomarkers that are involved in cell cycle regulation 
have become of interest as potential predictors of outcome in 
adjuvant chemotherapy.
  Cyclins, their associated cyclin-
dependent kinases, and cyclin-dependent
  kinase inhibitory 
proteins play a central role in cell cycle
 progression and may 
also affect response to chemotherapy [43,44].
 
In vitro studies 
suggested that overexpression of p27
Kip1 is associated
 with 
resistance to anticancer drugs [44-46]. Up regulation of
 
p27
Kip1 mediates drug resistance both in tumor cells and pro-
tects small-cell lung carcinomas from apoptosis, whereas 
downregulation of p27
Kip1 expression by antisense oligonu-
cleotides reduces intercellular
 adhesion, increases cell prolif-
eration, and enhances drug sensitivity
 of tumor cells [44-47]. 
Therefore, p27
Kip1 downregulation may contribute to chemo-
therapy
 sensitivity by cell cycle transition
 delay and by in-
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and/or predictive value of cell cycle regulators (p27
Kip1, 
p16
INK4A, cyclin D1, cyclin D3, cyclin
  E, and Ki-67) has 
been evaluated in NSCLC patients who were enrolled in the 
IALT trial. These biomarkers were assessed by IHC analysis 
in tumor sections
 from 783 patients. A relationship has been 
observed between the p27
Kip1 status and the benefit
 of cis-
platin-based chemotherapy (P=0.02). Among patients with 
p27
Kip1-negative tumors, patients who were treated with cis-
platin-based chemotherapy
  had a longer OS time than pa-
tients in the control
 group (HR:0.66; 95% CI, 0.50 to 0.88; 
P=0.006). In patients with p27
Kip1-positive tumors, the OS 
was not different between patients treated with chemother-
apy and controls (HR:1.09; 95%
 CI, 0.82 to 1.45; P=0.54). 
Furthermore, in p27
Kip1-negative
 patients, the MST was 13 
months longer
 in the chemotherapy group compared with the 
control group (58
 and 45 months, respectively). Comparable 
results
 were obtained when the p27
Kip1 score was analyzed as 
a continuous
 variable (P=0.03). When the analysis was fo-
cused
  on the chemotherapy arm, patients with p27
Kip1-
positive tumors
  experienced a shorter OS compared with 
patients
  with p27
Kip1-negative tumors (HR:1.35;
  95% CI, 
1.02 to 1.80; P=0.04). In contrast to p27
Kip1, none of other 
cell
 cycle regulators was able to predict the benefit for adju-
vant chemotherapy in this study [48].
 
  Since both ERCC1 and p27
Kip1 could be independent pre-
dictive factors in patients with resected NSCLC receiving 
adjuvant cisplatin-based chemotherapy, combining the de-
termination of the expression of these proteins their predic-
tive value could further increase. In the molecular analysis of 
the IALT trial, the major benefit from adjuvant treatment 
was observed in patients whose tumor specimens were nega-
tive for both biomarkers (HR 0.52, 95% CI 0.36-0.74) as 
compared to patients whose cancer were positive for both 
proteins (HR:1.27, 95% CI 0.77-1.84) [49]. 
Class III -Tubulin  
  -Tubulin is one of the major components of microtu-
bules which are complex polymers consisting of tubulin di-
mers (containing one  tubulin plus one  tubulin molecule) 
and a variety of mictotubule-associated proteins (MAPs), 
including   protein, microtubule associated protein 4, and 
stable tubule-only polypeptide proteins [50].  
  In humans, at least six distinct -tubulin isotypes (classes 
I, II, III, Iva, IVb, and V) have been reported, and their 
expression profile differs among tissues [51]. Class III -
tubulin (TubIII) differs from other tubulin isotypes in its 
amino acid sequence and post-translational modifications, 
which include phosphorylation and polyglutamylation [52]. 
In vitro studies showed that up-regulation
 of TubIII in lung 
and ovarian tumor cell lines confered resistance
  to do-
cetaxel/paclitaxel [53–55]. Furthermore, overexpression
  of 
TubIII in advanced ovarian, breast, and gastric cancers
  is 
generally associated with resistance to paclitaxel treatment 
and with a poor prognosis
  [56–58]. Several studies have 
shown that
 the level of TubIII (assessed by IHC or other
 
techniques) may be both a prognostic and a predictive factor
 
in advanced NSCLC. Twenty-five tumor specimens from 
advanced NSCLC patients treated with vinorelbine/cisplatin 
have been analyzed using QPCR. High TubIII
 mRNA lev-
els correlated with inferior outcome in advanced NSCLC   
 
patients
 treated with anti-tubulin agents [39]. It has also been 
shown a relationship between the high level of expression of 
TubIII in NSCLC tumor samples of patients treated with 
vinorelbine and the rate of progression following therapy. 
High expression of TubIII also correlated with shorter PFS 
and OS (P=0.002 and P=0.001 respectively) [59]. 
  In advanced NSCLC patients treated with paclitaxel-
based regimens, whose tumors expressed low levels of class 
III  tubulin isotype, a better RR, longer PFS and OS (P< 
0.001, 0.004, and 0.002, respectively) have been reported 
[60].
 The effect of TubIII
 on patient outcome and benefit 
from adjuvant chemotherapy has been recently investigated. 
Tumor tissues from 265 of the 482 patients enrolled in the 
NCIC-JBR.10 trial were analyzed for TubIII expression by 
IHC. High tubulin expression was significantly associated 
with poorer relapse-free survival (RFS) (HR:1.92; 95% CI, 
1.16-3.18; P=0.01), and a similar trend was seen
  for OS 
(HR:1.72; 95% CI, 1.02-2.88; P=0.04) in absence of adju-
vant chemotherapy treatment; conversely tubulin expression
 
was not a statistically significant predictor of outcome in
 the 
patients assigned to receive chemotherapy: RFS (HR:1.10;
 
95% CI, 0.62-1.95; P=0.75), OS (HR:1.11; 95% CI, 0.65-
1.88;
 P=0.7). The adverse prognostic value of high tubulin 
III expression is in accord to prior data reported in advanced 
NSCLC setting. Among the 133 high tubulin expressor pa-
tients, those receiving
  chemotherapy (68/133) had signifi-
cantly improved RFS (HR:0.45; 95% CI,
  0.27-0.75; P= 
0.002) and a trend toward improved OS (HR:0.64;
 95% CI, 
0.39-1.04; P=0.07) as compared with patients (65/133) in the 
observation
 arm. In the low
 tubulin group, no significant dif-
ference in RFS (HR:0.78; 95%
 CI, 0.44-1.37; P=0.4) or OS 
(HR:1.00; 95% CI, 0.57-1.75;
 P=0.99) was seen according to 
treatment assignment (surgery alone or adjuvant chemother-
apy) [61]. These results are in contrast to the data observed 
in advanced NSCLC, in which low tubulin III expression 
was correlated to higher RR to chemotherapy regimens 
which contain anti-microtubule drugs [39,59-60]. However, 
considering these results, further evaluation of the role of 
TubIII as a marker of chemosensitivity is necessary. 
Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)  
  The small guanosine triphosphate (GTP) binding
 protein 
Ras plays an important role in mediating multiple intracellu-
lar
 signal transduction pathways, including growth, apopto-
sis, and differentiation.
 Active GTP-bound Ras interacts with 
its downstream effectors
  and regulates the transduction of 
proliferative signals through
 the Raf/mitogen-activated pro-
tein kinase pathway and of the
  apoptosis through the 
Nore1/MstI and phosphatidylinositol 3'-kinase
 pathway [62]. 
  Activating mutations in the RAS family member were 
found approximately in 15-30% of lung cancers and resulted 
in MAPK pathway activation. These mutations are most fre-
quently detected in codons 12 and 13 in the exon 2 of the K-
RAS gene [63,64] and in patients with a history of substan-
tial cigarette use [65]. 
  Among 482 patients with completely resected early stage 
NSCLC enrolled in the JBR-10 clinical trial, the status of ras 
mutation (analysis of codons 12,13 and 21 of Harvey-ras, K-
ras and N-ras) was evaluated in 450 (93%) tumor specimens. 
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tients with wild type K-ras gene who did not receive chemo-
therapy the median survival was 74 months, whereas it was 
not reached in chemotherapy group (HR:0.69, 95% CI 0.49-
0.98, P=0.03). In patients whose tumors contained K-ras 
mutations, adjuvant chemotherapy conversely did not im-
prove survival (HR:0.95, 95% CI 0.53-1.71, P=0.87) [9]. 
EGFR  
  The Epidermal Growth Factor Receptor (EGFR) is a 
member of the ErbB family of cell membrane growth factor 
receptors that are important mediators of cell growth, differ-
entiation, and survival. EGFR is a 170 KDa transmembrane 
glycoprotein, with an intracellular domain that serves as the 
site of protein tyrosine kinase activity [66]. The EGFR is 
frequently overexpressed and/or abnormally activated in 40-
80 % of NSCLC [67]. The blockade of EGFR signalling in 
cancer cells not only determines the inhibition of cell prolif-
eration but also has other effects that could be relevant for 
the clinical activity including induction of apoptosis; anti-
angiogenesis through inhibition of angiogenic growth factor 
production; inhibition of invasion and metastasis; potentia-
tion of anti-tumor activity of cytotoxic drugs and of radio-
therapy [68]. 
  Two types of anti-EGFR targeting agents have reached 
advanced clinical development: monoclonal antibodies 
(Mabs) and small molecule inhibitors of the EGFR tyrosine 
kinase enzymatic activity (TKIs). Among EGFR-TKIs, er-
lotinib is currently approved worldwide for the treatment of 
chemotherapy-resistant advanced NSCLC patients, while the 
use of gefitinib is restricted to Asian countries. 
  Several researchers have identified somatic mutations in 
the EGFR gene and have discovered that these mutations 
were associated with a higher likelihood of clinical response 
to treatment with gefitinib and erlotinib [15-16,69]. EGFR 
gene mutations were most frequently detected in a subpopu-
lation of NSCLC patients with characteristics associated 
with a better treatment outcome: female sex, non smokers 
patients, Asian origin, adenocarcinoma histology. The more 
common EGFR mutations are an in frame deletion in exon 
19 around codons 746 to 750 and a missense mutation lead-
ing to leucine to arginine substitution at codon 858 (L858R) 
in exon 21 [70]. In a large number of retrospective clinical 
trials, it has been suggested that NSCLC patients treated with 
EGFR-TKIs, whose tumors are carrying sensitizing EGFR 
mutations achieve an improvement of survival [71-78], al-
though this effect has not always been demonstrated [17,79-
81].  
  Different somatic EGFR gene mutations may confer di-
verse tumor activation profiles that lead to variations in both 
natural history and clinical course after treatment with er-
lotinib or gefitinib. The relationship between the two most 
common types of somatic EGFR mutations has been evalu-
ated. Emerging data suggest that patients with NSCLC and 
EGFR exon 19 deletion have a longer survival following 
treatment with gefitinib or erlotinib compared with those 
with the L858R mutation [82-84]. 
  Several prospective clinical trials have been conducted to 
determine the RR to EGFR-TKIs in Caucasian and in East 
Asian patients carrying EGFR somantic mutations [85-89]; 
these data suggest that EGFR-TKIs are highly active treat-
ment for patients harbouring EGFR gene mutations; how-
ever, at this time there are no data from prospective random-
ized clinical trial which demonstrate a survival advantage for 
NSCLC patients with EGFR mutation treated with EGFR-
TKIs.  
  The potential predictive role of EGFR gene amplification 
by fluorescence in situ hybridization (FISH) in patients 
treated with gefitinib or erlotinib is emerging from several 
retrospective analyses [17,76]. In the retrospective analysis 
of a phase III randomized, double-blind, placebo-controlled 
trial (the BR21 study), EGFR FISH-positive patients ran-
domized to receive erlotinib had a significantly superior sur-
vival (HR:0.44, P=0.01), as compared with FISH-positive 
patients randomized into the placebo arm (HR:0.44, P=0.01). 
Similar results were observed in the Iressa Survival Evalua-
tion in Lung cancer (ISEL) study, a randomized, placebo-
controlled, phase III clinical trial, that has investigated the 
effect of gefitinib on survival in chemotherapy refractory 
advanced NSCLC patients. Significantly, EGFR FISH-
positive status was associated with certain clinical and bio-
logical characteristics predictive for EGFR-TKI sensitivity, 
such as female sex, never-smoking history, and the presence 
of EGFR mutations. In another phase III clinical trial, the 
Iressa NSCLC Trial Evaluating Response and Survival 
Against Taxotere (INTEREST trial), which has met the pri-
mary endpoint of noninferiority of gefitinib as compared to 
docetaxel, patients with high EGFR gene copy numbers re-
ceiving gefitinib had a MST of 8.4 months as compared to 
7.5 months in those treated with chemotherapy (HR:1.09; 95 
%CI 0.78-1.15 P=0.6199) [90]. In a phase II randomized 
study named IRESSA in NSCLC vs Vinorelbine Investiga-
tion in The Elderly (INVITE trial), comparing gefitinib to 
vinorelbine in chemonaïve elderly patients with advanced 
NSCLC, PFS, the primary end point of this study, was not 
significantly different between the two arms (2.7 and 2.9 
months for gefitinib and navelbine, respectively). Explora-
tory analyses in EGFR FISH-positive subgroup, HRs for 
gefitinib as compared to vinorelbine were 3.13 (95% CI 
1.45, 6.76) for PFS and 2.88 (95% CI 1.21, 6.83) for OS, 
surprisingly favoring chemotherapy to gefitnib treatment 
[91]. 
  The data emerging from advanced stage NSCLC patient 
warranted the investigation of EGFR inhibitors in the adju-
vant setting. However, two adjuvant trials of gefitinib vs 
placebo in unselected patients have been stopped early in 
Japan, due to toxicity (interstitial lung disease), and in Can-
ada, due to negative results of the ISEL trial in advanced 
disease. To date, erlotinib is under investigation in adjuvant 
setting in selected patients. In the Randomized phase III 
double-blind trial in adjuvant NSCLC with Tarceva (RADI-
ANT trial) patients with resected stage IB to IIIA NSCLC 
which are positive for EGFR detected by FISH or IHC are 
being enrolled. Patients are randomized to receive two years 
of erlotinib at standard dose versus placebo after four cycles 
of adjuvant chemotherapy containing platinum agents. In this 
study, it will be also retrospectively analyzed the mutational 
status of EGFR and K-ras genes.  
  Nevertheless, it may be of major interesting to plan clini-
cal trials in the adjuvant setting by selecting patients through 
the knowledge of EGFR or K-ras gene mutations. The Potential Role of Pharmacogenomic and Genomic  Current Genomics, 2008, Vol. 9, No. 4    257 
Other Potential Biological Markers 
Multidrug
 Resistance Proteins (MRP) 
  The MRP family, also known as C group of adenosine 
triphosphate (ATP)-binding cassette
 transporters, consists of 
13 structurally related
 ATP-binding cassette transporters that 
are involved in the transport
 of various molecules. Overex-
pression of
 MRP1 or MRP2 in tumor cells confers resistance 
to various anticancer
 drugs [92-93]. 
  The prognostic and/or predictive value of the different
 
MRPs in malignant diseases is under investigation.
 Recently, 
IHC analysis of MRP1 and MRP2 was retrospectively per-
formed in
 tumor sections of 782 patients from IALT trial.
 
Patients with MRP2-positive tumors had a significantly 
shorter OS than patients with MRP2-negative tumors 
[HR:1.37; 95% CI, 1.09-1.72; P=0.007]. Median OS
 was 9 
months longer in the MRP2-negative group compared with
 
MRP2-positive tumors (54 and 45 months,
 respectively). In 
contrast, no significant
  correlation between MRP1 expres-
sion and OS of
 the patients was reported.
  
  However neither the expression of MRP1 nor of MRP2 is 
associated to the benefit of cisplatin-based chemotherapy 
[94].  
Apoptotic Markers 
  An analysis of apoptotic markers such as the death recep-
tor Fas, its ligand FasL and survivin, a G2-M cell cycle regu-
lated protein with anti-apoptotic properties, has been recently 
performed. Among 773 specimens from the IALT trial 
which were analyzed by IHC, 73% were Fas negative, 49% 
FasL negative and 54% survivin positive. Fas positivity cor-
related with vascular invasion, while FasL correlated with 
histology (higher in adenocarcinoma) and pleural invasion. 
Survivin was lower in adenocarcinoma, higher in males and 
lower in older patients. None of these biomarkers appears to 
be related to prognosis; only the ratio of a Fas to FasL > or = 
1 was associated with longer survival (HR:0.72; P=0.02). 
None of these markers had predictive value for chemosensi-
tivity at the level of significance 0.01. However, a borderline 
predictive value was observed for FasL negative (HR:0.69) 
as compared with FasL positive (HR:1.03; P=0.06) samples, 
as well as for Fas:FasL ratio >1 (HR:0.51) as compared with 
a ratio of 1 (HR:1.13) or a ratio 1 (HR:0.80; P=0.05) [95].  
BRCA1 
  BRCA1 is implicated
 in transcription-coupled nucleotide 
excision repair (TC-NER),
 and modulation of its expression 
determine modification of TC-NER
  and then  radio and 
chemo-resistance. It is a component of
 a large DNA repair 
complex named the BRCA1-associated genome
 surveillance 
complex, containing mismatch repair
  proteins. Therefore, 
BRCA1 may be a potential role in mismatch
 repair mecha-
nisms [96-97]. BRCA1 overexpression has been correlated 
to apoptosis
  through the c-Jun N-terminal kinase pathway 
[98], which is activated
 by cisplatin-induced DNA damage 
[99]. 
 In  vitro studies have shown that BRCA1 can regulate 
differential sensitivity to different classes of chemotherapy 
agents [100]. It has been demonstrated that BRCA1 abro-
gates the apoptotic phenotype induced by a range of cyto-
toxic agents such as cisplatin, bleomicin, and determines 
remarkable response to several antimicrotubule drugs [100-
102]. On the basis of the evidence for the role of BRCA1 in 
breast
  and ovarian cancers, it has been suggested that 
BRCA1 mRNA expression
 could also play an important role 
in predicting differential
  chemotherapy sensitivity in 
NSCLC. BRCA1 mRNA expression has been evaluated in 
55 surgically
  resected NSCLC patients who had
  received 
neoadjuvant gemcitabine/cisplatin chemotherapy by RT-
QPCR. Patients were divided according to the gene expres-
sion values into quartiles. In these locally advanced NSCLC 
patients, BRCA1 mRNA expression seems to predict out-
come. Median survival was not reached for patients with low 
BRCA1 level, whereas in the
 two middle quartiles, it was 
37.8 months (95% CI, 10.6–65),
 and for the 12 patients in the 
top quartile, it was 12.7 months
 (95% CI, 0.28-28.8) (P=0.01) 
[103]. This findings may be indicative that patients with high 
levels could better respond to non platinum-based chemo-
therapy but more to antimicrotubules agents. 
  A pilot study of adjuvant chemotherapy according to 
BRCA1 mRNA levels has been conducted in 88 completely 
resected stage II-III NSCLC patients. Patients with higher 
BRCA1 levels were treated with docetaxel, while cisplatin-
based chemotherapy was reserved to those with lower 
BRCA1 levels. In the preliminary interim analysis, event 
free survival was similar in both groups [104]. Recently, a 
series of genes involved in DNA repair pathways and in me-
tastasis formation were evaluated in 126 chemo-naive stage 
I- III A NSCLC patients who have received only surgical 
resection and were analyzed by RT-QPCR. For 77 patients 
with low levels of BRCA1, event-free survival has not been 
reached, while it was 22 months for those with high levels 
(P=0.04). For 83 patients with low levels of BRCA1, median 
survival has not been reached, while it was 29 months for 
those with high levels (P=0.04). The Cox proportional haz-
ards model selected pathological stage IIIA and BRCA1 ex-
pression as independent prognostic factors for survival. The 
HR was 7.91 (95%CI, 2.27-27.54; P=0.001) for stage IIIA 
and 1.98 (95%CI, 1.11-6; P=0.02) for BRCA1 expression. In 
an independent validation cohort of 58 stage IB-IIB NSCLC 
patients, BRCA1 was also confirmed as the only independ-
ent prognostic markers [104]. BRCA1 mRNA expression 
may offer a supplementary information to tailored adjuvant 
chemotherapy for early NSCLC patients, but further analysis 
are necessary to clarify the role of this biomarker.  
Gene Expression Profiles 
 Gene-expression
 profiling has recently been developed in 
several studies to indentify clusters of genes whose concomi-
tant expression pattern may characterize prognosis, stratify 
risk and guide treatment decision for NSCLC patients [105-
111]. 
  Initially, genes have been identified as responsible for the 
aggressiveness of squamous cell carcinoma of the lung in a 
small group of stage I squamous cell carcinoma (SCCs), and 
also in other studies in which patients were unstratified for 
histopathologic subtype of lung cancer [105-107]. 
  Gene expression profile has been analyzed in 51 com-
pletely resected stage I-III lung SCCs. Gene sets have been 
compared among individuals who remained disease-free
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a minimum of 36 months with those from individuals whose
 
disease recurred within 18 months of complete resection. 
 Using  Cox
 proportional modelling, a 71-gene signature 
has been reported which was capable to predict recurrence 
and a set of 79-gene signature predictive for cancer-related
 
death. 
  By joining these two signatures, a 111-gene signature 
was identified which was able to predict
 outcome in an inde-
pendent test set of 58 SCCs with a 72% accuracy; this
 signa-
ture also predicted differences in survival [log-rank P= 
0.0008; HR 3.8; 95% CI,
 1.6–8.7]. This set of genes included
 
genes with biological relevance to disease recurrence, such
 
as cell growth and movement, cell communication and cell 
signalling [108]. In a similar clinical trial, it has been identi-
fied a 54-gene signature set in early stage adenocarcinoma 
lung cancer capable of predicting risk of recurrence in two 
independent validation cohorts. This signature predicted out-
come independently of tumor stage and lymph-node [109]. 
  Recently, it has been conducted a meta-analysis of 
datasets from seven different microarray studies on NSCLC 
for differentially expressed genes related to survival time 
(under 2 y and over 5 y). A gene signature consisting of 64 
genes has been identified. Using this set of genes, it has been 
demonstrated a significantly worse OS for high-risk patients 
as compared to low-risk patients. These 64 genes includes 
eleven genes which are related to cancer metastasis and eight 
genes which are involved in apoptosis. The resulting signa-
ture is useful in predicting survival of stage I NSCLC and 
might be useful in making treatment decisions [110]. 
  A total of 198 tumor specimes from three different co-
horts of patients with early-stage NSCLC has been analayzed 
and a gene expression profile named the lung metagene 
model has been identified. These gene profile may predict a 
risk of disease recurrence with an accuracy of 93% in a co-
hort of 91 patients. This model was superior to a predictive 
model generated with the same methods but which includes 
only clinical characteristics (age, sex, stage, histology and 
smoking). When this model has been applied to the two vali-
dation cohorts, the predictive accuracy was superior to 70%. 
The lung metagene model also permits to identify a sub-
group of stage IA NSCLC patients at high risk for recur-
rence. For these patients the survival rate at four years was 
less than 10%. However, the impact on response to chemo-
therapy in the high-risk group should be studied in a pro-
spective randomized trial [111]. 
  There is a lack of overlap in gene expression signatures 
in the several trials and a few or none genes were common to 
the different signatures. Moreover, at the moment none of 
the studies of NSCLC gene signatures so far published have 
been able to provide data to help the choice of chemotherapy 
in the adjuvant setting.  
CONCLUSIONS  
  Improving outcomes for early-stage NSCLC is a major 
clinical research area, considering that a significant percent-
age of stage I patients develop recurrent disease within 5-
years of complete curative lung resection. Conventional 
clinical prognostic markers fail to predict relapse accurately. 
The identification of predictive factors guiding the clini-
cian’s choice, considering both the genetic profile of the pa-
tients and the biological characteristics of the disease could 
optimize the efficacy of current therapies in the adjuvant 
setting. 
  The discovery of genes that influence drugs activity and 
the toxicity related to treatment seems an interesting way to 
tailor individual therapy. The data summarized in this review 
are encouraging and indicate a progress towards the era of 
customized therapy. However, these data are not sufficient to 
support the routine use of pharmacogenetic markers in the 
clinical practice. In fact, several molecular markers have 
been tested by using using tissue samples from retrospective 
cohort studies; for these reason, further research is needed to 
identify valid and standardized laboratory methodologies for 
molecular assays and future prospective clinical trials using 
pharmacogenetic markers are required in the adjuvant set-
ting. 
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